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 Autoimmune lymphoproliferative syndrome (ALPS; OMIM#601859) is a 
rare apoptotic disorder attributable to a failure in FAS-mediated apoptosis 
signaling [1, 2] that leads to lymphadenopathy, hypersplenism, and autoimmune 
cytopenia with childhood onset.  The major determinants of morbidity and 
mortality in ALPS are the severity of the autoimmune disease; about 10% of 
patients develop malignant lymphoma [3-5].  We encountered a 23-year-old male 
with ALPS type 1A who developed a secondary anaplastic astrocytoma.  This is 
the first reported case of its kind. 
Malignant astrocytoma is now known to develop via 2 different pathways [6].  
Low-grade diffuse astrocytomas, commonly accompanied by IDH1 (> 80%) and TP53 (> 
60%) mutations, eventually progress to a more malignant form of anaplastic astrocytoma 
followed by secondary glioblastoma [7, 8].  We present an extremely rare case of secondary 
anaplastic astrocytoma in an ALPS patient and document genetic alterations in the course of 
tumour progression, i.e. germline FAS mutation without IDH mutation. 
The patient was a 23-year-old male with ALPS type 1A manifesting a germline FAS 
mutation that resulted in the failure of FAS-mediated apoptosis signal transduction [9].  His 
sister had non-Hodgkin's lymphoma, his mother was asymptomatic.  His maternal 
grandmother had died at the age of 70 of secondary glioblastoma without signs of 
immunodeficiency.  On his father's side there was no family history of immunodeficiency 
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diseases or brain tumours (Fig. 1).  At the age of 9 years the patient manifested precocious 
puberty and was treated with anti-FSH therapy.  Brain MRI scans obtained at that time 
revealed a diffuse T2 hyperintensity lesion in the right temporo-occipital lobe that was 
suspected to be a low-grade glioma (Fig. 2A, B).  The lesion was followed by annual MRI 
study and remained unchanged until he was 22 years old.  At the age of 23 he suffered 
severe headache lasting for one month.  Gd-enhanced T1-weighted MRI revealed a huge 
ring-enhanced mass in the right temporal lobe adjacent to the previously-recognised diffuse 
lesion (Fig. 2C, D).  He underwent surgical resection of the enhanced mass and biopsy of 
the adjacent diffuse lesion.  The resected mass was diagnosed as malignant glioma and he 
received radiochemotherapy (local irradiation with 50 Gy and oral temozolomide).  At 
present, 24 months after the operation, he remains free of tumour recurrence. 
Paraffin-embedded tissues obtained at surgery were stained with hematoxylin and 
eosin and then stained for immunohistochemical study using antibodies for GFAP 
(monoclonal, 1:300, Dako Co., Carpinteria, CA, USA), S100 (monoclonal, 1:500, Dako), 
synaptophysin (monoclonal, 1:20; SY-38, Chemicon International, Temecula, CA, USA), 
MIB-1 (monoclonal, 1:200, Funakoshi, Tokyo, Japan), and TP53 (mouse monoclonal, 1:20; 
DO-7, Dako).  The histological diagnosis was made independently by 2 pathologists. 
DNA was extracted from snap-frozen tissues with TissueGen (Nippongene, Toyama, 
Japan) according to the manufacturer’s instructions.  Direct sequencing of exons 5-8 of the 
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TP53 gene and of the junction between exon 7 and intron 7 of the FAS gene was with the 
Big-Dye DNA sequencing system (Applied Biosystems, Branchburg, NJ, USA) as described 
elsewhere [10-12]. 
Frozen tissue was subjected to dual-colour FISH at SRL Co. (Tokyo, Japan).  Paired 
FISH probes for 1p36/1q25, 19p13/19q13, and CEP7/EGFR (Vysis, Downers Grove, IL) 
were used for detecting loss of heterozygosity (LOH) at 1p and 19q [13] and for 
amplification of the EGFR gene [14], respectively.  To detect duplications at chromosome 
band 7q34 containing a BRAF-KIAA1549 gene fusion, a FITC-labeled locus-specific probe 
(RP11-355D18 corresponding to KIAA1549) and a digoxigenin-labeled locus-specific probe 
(726N20 corresponding to BRAF) were used [15]. 
On pathological examination, tissue from the newly-developed tumour exhibited a 
biphasic pattern comprised primarily of piloid cells without an angiocentric pattern on a 
myxoid background (Fig. 2E).  High-cellular regions contained compact cells with mitoses 
(Fig. 2F); the maximum MIB-1 labeling index was 34.3% (Fig. 2G).  Imunohistochemically, 
the tumour cells were positive for TP53 (Fig. 2H), GFAP, and S100 but negative for 
synaptophysin.  They tended to infiltrate perivascular spaces (Fig. 2I).  Rosenthal fibers 
and eosinophilic granular bodies were absent, a finding essential for a diagnosis of pilocytic 
astrocytoma.  The tumour tissue exhibited no necroses or microvascular proliferation, a 
finding incompatible with a diagnosis of glioblastoma.  The final histological diagnosis was 
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anaplastic astrocytoma WHO grade III rather than pilocytic astrocytoma or glioblastoma.  
Considering radiological-, immunohistochemical-, and genetic findings, the anomalous T2 
hyperintensity on MRI, positivity for GFAP, and the presence of a TP53 mutation (Fig. 3B), 
the long-standing diffuse lesion was diagnosed as a diffuse astrocytoma WHO grade II (Fig 
2J). 
Direct sequencing of the TP53 gene through exons 5-8 [10] revealed a missense 
mutation in exon 8 c.830G>T (p.Cys277Phe) in both the new- and the long-standing tumour; 
the mutation of the old tumour was homozygous and that of the new tumour was 
heterozygous (Fig. 3A, B).  DNA obtained from the patient’s blood did not manifest the 
TP53 mutation, indicating that it was somatic (Fig. 3C).  Direct sequencing of the FAS gene 
in both tumour- and blood cells identified a heterozygous FAS mutation at the splicing site of 
intron 7 that is known to produce a dominant-negative form of FAS [9] (Fig. 3D).  Direct 
sequencing of exon 4 of the IDH1 and the IDH2 gene [16, 17] did not reveal mutations in 
either tumour.  FISH study of both tumours yielded no evidence of EGFR gene 
amplification [14], LOH in chromosome 1p/19q [13], or BRAF gene rearrangement [15], 
findings that are often returned in glioblastoma, oligodendroglioma, and pilocytic 
astrocytoma, respectively. 
 To our knowledge, among 200 reported ALPS patients, ours is the first patient with 
malignant glioma [3].  Approximately 10% of ALPS patients manifested malignant 
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lymphoma [3,4], suggesting that the FAS mutation per se is carcinogenic.  In addition, the 
mutation may play a role in tumourigenesis in other types of malignancies including basal- 
[18] and squamous cell carcinoma [19], malignant melanoma [20], and non-small cell lung 
cancer [21-23].  In our patient the possible association between the development of 
anaplastic astrocytoma and the FAS mutation is unclear because the mutation has not been 
reported in gliomas.  The coexistence of FAS- and TP53 mutations is strongly carcinogenic 
in some types of tumour [18, 22].  Interestingly, our patient with a family history of ALPS 
developed 2 astrocytic tumours, suggesting that the FAS mutation may play an important role 
in some types of astrocytic tumour as it does in other types of malignancies, especially in the 
presence of a TP53 mutation. 
Our patient's newly-developed tumour was positive for TP53, probably due to a 
missense TP53 mutation in exon 8 c.830G>T (p.Cys277Phe).  The pre-existence of a 
low-grade lesion with the identical heterozygous TP53 mutation and the absence of EGFR 
amplification suggests that the development of his anaplastic astrocytoma followed the 
“classical” pathway for secondary glioblastoma development characterised by the presence of 
a less malignant precursor lesion and a high incidence (> 60%) of TP53 mutations without 
EGFR amplification [24-26].  The heterogeneous TP53 status of the long-standing- (Fig. 
3B) and the absence of the normal TP53 allele in the newly-developed tumour (Fig. 3A) 
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suggest that the eventual loss of the normal TP53 allele is associated with malignant 
transformation. 
The pathological features of his newly-developed tumour included the presence of a 
portion that resembled pilocytic astrocytoma; it consisted of piloid cells with a myxoid 
background and small cells with high cellularity.  The absence of Rosenthal fibers and 
eosinophilic granular bodies, and the lack in his newly-developed tumour of BRAF 
rearrangement, a hallmark of pilocytic astrocytoma (~70%) [27-29], argued against a 
diagnosis of pilocytic astrocytoma.  We based our histological diagnosis of anaplastic 
astrocytoma WHO grade III on the absence of definite necrosis and microvascular 
proliferation. 
IDH1/2 mutations are commonly detected in low-grade astrocytomas and 
oligodendrogliomas, and in the course of progression from low-grade astrocytoma, secondary 
glioblastomas tend to manifest IDH1/2 mutations [7, 30].  However, neither his 
long-standing- nor his newly-developed tumour manifested IDH1/2 mutations, suggesting 
that in our patient the path of tumour progression was different from the ordinary pathway to 
secondary glioblastoma. 
This is the first report describing the development of glioma in an ALPS patient.  We 
posit that germline FAS- and somatic TP53 mutations were associated with the development 
of his secondary anaplastic astrocytoma from his pre-existing less malignant diffuse 
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astrocytoma.  Furthermore, the absence of IDH1/2 mutations suggests an uncommon 
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Figure Legends 
Fig. 1. 
The pedigree of the patient's family.  Two secondarily-developed gliomas and a 
non-Hodgkin's lymphoma were part of the family history. 
 
Fig. 2 
(A-D) MRI images showing Gd-enhanced T1- and T2-weighted MR images acquired in 
1993 when the patient was 9 years old (A, B) and in 2008 when he was 23 years old 
(C,D).  Note the ring-enhanced tumour with peritumoural edema and the midline 
shift adjacent to the diffuse long-standing lesion. 
(E-J) Pathological features of the newly-developed tumour (E-H), adjacent brain tissue (I), 
and the long-standing lesion (J).  Hematoxylin and eosin staining of tissue from the 
newly-developed tumour shows that the tumour tissues consist of piloid tumour cells 
on a myxoid background (E) and high-cellular regions (F).  There are no Rosenthal 
fibers, eosinophilic granular bodies, microvascular proliferation, or necrosis evident 
in the tumour tissues.  (G) MIB-1 staining revealed a highly cellular region with 
high proliferative activity (labeling index >30%).  (H) The tumour cells were 
positive for TP53 antibody staining.  (I) The cells infiltrated into surrounding brain 
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tissue via perivascular spaces.  (J) Tissue from the long-standing lesion showed the 
diffuse distribution of well-differentiated fibrillary cells. 
 
Fig. 3 
(A-C) Direct sequencing of the TP53 gene.  A missense mutation in exon 8 c.830G>T 
(p.Cys277Phe) was observed in both the new (homozygous) (A) and long-standing 
(heterozygous) (B) tumour. 
(C) DNA from the patient's blood did not manifest the TP53 mutation. 
(D) Direct sequencing of the FAS gene revealed a heterozygous FAS mutation at the 
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